Estimation of mortality savings due to a national program for diabetes care

European Journal of Internal Medicine

Volumn 20, Issue 3, 2009, Pages 307-312

  Dreiher, Jacob ^a,b   Ginsberg, Gary ^c   Rabinowitz, Gad ^b   Raskin Segal, Anat ^b   Weitzman, Ron ^b   Porath, Avi ^a,b  

^a CLALIT HEALTH SERVICES   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c MINISTRY OF HEALTH   (Israel)

Author keywords

Diabetes mellitus; Evaluation; Managed care; Quality indicators; Quality of care

Indexed keywords

HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN;

ARTICLE; DIABETES CONTROL; DIABETES MELLITUS; FEMALE; GLYCEMIC CONTROL; HEALTH PROGRAM; HEMOGLOBIN BLOOD LEVEL; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT CARE; PREVALENCE; QUALITY ADJUSTED LIFE YEAR;

DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; ISRAEL; MALE; MANAGED CARE PROGRAMS; NATIONAL HEALTH PROGRAMS; PREVALENCE; PRIMARY HEALTH CARE; QUALITY OF HEALTH CARE; SEX DISTRIBUTION;

EID: 64749107071     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2008.09.003     Document Type: Article

References (34)

1. Cook D.J., and Guyatt G.H. Interpreting, integrating and individualizing evidence about the prevention of diabetic nephropathy. Ann Intern Med 131 (1991) 707-708
2. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diab Res Clin Pract 28 (1995) 103-117
3. Khaw K.T., Wareham N., Bingham S., Luben R., Welch A., and Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 141 (2004) 413-420
4. Kuusisto J., Mykkanen L., Pyorala K., and Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43 (1994) 960-967
5. Selvin E., Marinopoulos S., Berkenblit G., Rami T., Brancati F.L., Powe N.R., et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141 (2004) 421-431
6. Stratton I.M., Adler A.I., Neil A.W., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2004) 405-412
7. Selvin E., Coresh J., Golden S.H., Brancati F.L., Folsom A.R., and Steffes M.W. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 165 (2005) 1910-1916
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
9. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
10. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
11. Eurich D.T., Majumdar S.R., Tsuyuki R.T., and Johnson J.A. Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. Diab Care 27 (2004) 1330-1334
12. Saaddine J.B., Cadwell B., Gregg W., Engelgau M.M., Vinicor F., Imperatore G., et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 144 (2006) 465-474
13. Porath A., Rabinovitz G., Raskin-Segal A., Weitzman R., and Ben Said S. Quality Indicators for Community Health Care in Israel 2003-2007 Public Report (2008). http://www.132.72.100.18/HealthReports/Download/public_report_English_2005-2007.pdf http://132.72.100.18/HealthReports/Download/public_report_English_2005-2007.pdf, Accessed 8 August 2008
14. Stevens R.J., Kothari V., Adler A.I., Stratton I.M., Holman R.R., and on behalf of the United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 101 (2001) 671-679
15. Goldfine A.B., and Beckman J.A. Life and death in Denmark: lessons about diabetes and coronary heart disease. Circulation 117 (2008) 1914-1917
16. Central Bureau of Statistics. Statistical Abstract of Israel 2006, No. 57, Jerusalem (2006). http://www1.cbs.gov.il/reader/shnatonenew.htm http://www1.cbs.gov.il/reader/shnatonenew.htm, Accessed 26 February 2007
17. Regional Office for Europe. European Health for All Database. http://data.euro.who.int/hfadb/, Accessed 26 February 2007.
18. Bell D.S.H. Advances in diabetes for the millennium: the heart and diabetes. Med Gen Med 6 (2004) 7
19. Potts J.L., and Thomas J. Traditional coronary risk factors in African Americans. Am J Med Sci 317 (1999) 189-192
20. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393
21. Gaede P., Lund-Andersen H., Parving H.-H., and Pedersen O. Effect of multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358 6 (2008) 580-591
22. Gaede P., Valentine W.J., Palmer A.J., Tucker D., Lammert M., Parving H.-H., et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the steno-2 study. Diabetes Care 31 8 (2008) 1510-1515
23. Clarke P.M., Gray A.M., Briggs A., Stevens R.J., Matthews D.R., and Holman R.R. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 48 (2005) 868-877
24. Rosen A.B., Hamel M.B., Weinstein M.C., Cutler D.M., Fendrick A.M., and Vijan S. Cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med 143 (2005) 89-99
25. World Health Organization. World Health Report 2002 - reducing risks, promoting healthy life. Statistical Annex, Table 4 (2002), Geneva 198-201. http://www.who.int/whr/2002/en/whr2002_annex4.pdf http://www.who.int/whr/2002/en/whr2002_annex4.pdf, Accessed 2 March 2007
26. UK Prospective Diabetes Study Group. Cost-effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 317 (1998) 720-726
27. Goldfracht M., and Porath A. Nationwide program for improving the care of diabetic patients in Israeli primary care centres. Diab Care 23 (2000) 495-499
28. HEDIS: The Health plan Employer Data and Information Set (HEDIS). The State of Health Care Quality 2005. NCQA: National Committee for Quality Assurance, USA (2006). http://www.ncqa.org http://www.ncqa.org, Accessed 2 March 2007
29. Gudbjornsdottir S., Cederholm J., Nilsson P.M., Eliasson B., and for the Steering Committee of the Swedish Diabetes Register. The National Diabetes Register in Sweden: an implementation of the St. Vincent declaration for Quality Improvement in Diabetes Care. Diabetes Care 26 (2003) 1270-1276
30. The CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287 (2002) 8542-8551
31. Clarke P., Gray A., Adler A., Stevens R., Raikou M., Cull C., et al. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia 44 (2001) 298-304
32. Zimmet P., Alberti K.G.M.M., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
33. Mainous III A.G., Baker R., Koopman R.J., Saxena S., Diaz V.A., Everett C.J., et al. Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the way. Diabetologia 50 (2007) 934-940
34. Goldie S.J. Chapter 15: Public health and cost-effectiveness analysis. J Natl Cancer Inst Monogr 31 (2002) 102-110